title: Receptor of advanced glycation end products (RAGE) positively regulates CD36 expression and reactive oxygen species production in human monocytes in diabetes.
abstract: BACKGROUND
  Advanced glycation end products (AGEs) engagement of a monocyte surface receptor (RAGE) induces atherosclerosis. AGEs also act as CD36 ligands. We studied reactive oxygen species (ROS) and CD36 expression after siRNA inhibition of RAGE expression in human monocytes.
  
  
  METHODS
  We isolated monocytes from: a) 10 type 2 diabetics, and b) 5 age- and sex-matched healthy individuals. CD36 expression and ROS production were evaluated before and after RAGE knockdown.
  
  
  RESULTS
  After incubation of monocytes with AGE + bovine serum albumin (BSA), CD36 expression and intracellular ROS increased significantly in all groups. In RAGE-knockdown monocytes, AGE-induced CD36 expression and ROS generation were also significantly inhibited.
  
  
  CONCLUSIONS
  Blocking RAGE expression using siRNA in human monocytes led to a significant inhibition of CD36 expression and ROS production, suggesting a positive interaction between RAGE, CD36 expression and ROS generation in monocytes.
authors.affiliation: First Propedeutic Internal Medicine Clinic, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. andyxanthis@yahoo.gr
authors.forename: A
authors.initials: A
authors.lastname: Xanthis
authors.forename: A
authors.initials: A
authors.lastname: Hatzitolios
authors.forename: S
authors.initials: S
authors.lastname: Fidani
authors.forename: C
authors.initials: C
authors.lastname: Befani
authors.forename: G
authors.initials: G
authors.lastname: Giannakoulas
authors.forename: G
authors.initials: G
authors.lastname: Koliakos
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D018955:CD36 Antigens / Q000096:biosynthesis / Q000187:drug effects / Q000235:genetics*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy / Q000235:genetics; D005260:Female; D005786:Gene Expression Regulation; D017127:Glycation End Products, Advanced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000187:drug effects / Q000235:genetics*; D017382:Reactive Oxygen Species / Q000097:blood*; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000378:metabolism*; D013050:Spectrometry, Fluorescence
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D018955:CD36 Antigens; D017127:Glycation End Products, Advanced; D034741:RNA, Small Interfering; D017382:Reactive Oxygen Species; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic